Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GM1 for nab-paclitaxel neurotoxicity in lung cancer
NCT02500810Phase 2Unknown
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Jul 2015
- Primary completion
- Jul 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of monosialotetrahexosylganglioside in neurotoxicity, sponsored by Peking University Cancer Hospital & Institute. Status: unknown.
02
Drugs
monosialotetrahexosylganglioside
03
Conditions
neurotoxicity
Beyond the preview
Go deeper on NCT02500810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02500810.